Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV000624988 | SCV000743369 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2015-12-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000624988 | SCV000823732 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2023-10-13 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg170*) in the G6PC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in G6PC are known to be pathogenic (PMID: 8182131). This variant is present in population databases (rs373345919, gnomAD 0.006%). This premature translational stop signal has been observed in individuals with glycogen storage disease type 1a (PMID: 10094563, 10797430, 15455297). ClinVar contains an entry for this variant (Variation ID: 522204). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000624988 | SCV000894122 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2022-04-29 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000624988 | SCV000917380 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2018-02-26 | criteria provided, single submitter | clinical testing | Variant summary: G6PC c.508C>T (p.Arg170X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (eg. c.1039C>T, p.Gln347X). Two of two in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.5e-05 in 121412 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in G6PC causing Glycogen Storage Disease Type Ia (2.5e-05 vs 0.0017), allowing no conclusion about variant significance. c.508C>T has been reported in the literature in multiple individuals affected with Glycogen Storage Disease Type Ia. These data indicate that the variant is very likely to be associated with disease. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. |
Mendelics | RCV000624988 | SCV001140452 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000624988 | SCV001163784 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | criteria provided, single submitter | clinical testing | ||
Greenwood Genetic Center Diagnostic Laboratories, |
RCV000624988 | SCV004099089 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2023-07-06 | criteria provided, single submitter | clinical testing | PVS1, PS3, PM2, PM3 |
Genome Diagnostics Laboratory, |
RCV000624988 | SCV000745678 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2017-05-19 | no assertion criteria provided | clinical testing | |
Clinical Genetics, |
RCV001701123 | SCV001918947 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Natera, |
RCV000624988 | SCV002093309 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2017-03-17 | no assertion criteria provided | clinical testing |